Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Healthcare Agencies II01:17

Healthcare Agencies II

There are various healthcare agencies in the United States—some of which are managed by religious institutions and others by different government branches.
Parish nursing is a growing specialty nursing profession that focuses on holistic healthcare, health promotion, and illness prevention. It blends professional nursing practice with a health ministry, focusing on health and healing within the context of a Christian community. Parish nurses serve as health educators, referral sources, and lay...
Robbers Cave04:49

Robbers Cave

During the 1950s, the landmark Robbers Cave experiment demonstrated that when groups must compete with one another, intergroup conflict, hostility, and even violence may result. At the Oklahoman summer camp, two troops of boys—termed the Rattlers and the Eagles—took part in a week-long tournament. During this time, their negativity culminated in derogatory name-calling, fistfights, and even vandalism and destruction of property. However, this work also revealed that such tension could be...
The Stanford Prison Experiment03:20

The Stanford Prison Experiment

The famous and controversial Stanford Prison Experiment, conducted by social psychologist Philip Zimbardo and his colleagues at Stanford University, demonstrated the power of social roles, social norms, and scripts.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring the Bone Marrow Microenvironment as a Therapeutic Barrier and Targetable Source of Crosstalk in Acute Myeloid Leukemia.

Blood and lymphatic cancer : targets and therapy·2026
Same author

Design, Synthesis, and Biological Evaluation of Efflux-Resistant Imatinib Derivatives.

Journal of medicinal chemistry·2025
Same author

Systems biology-enabled targeting of NF-κΒ and BCL2 overcomes microenvironment-mediated BH3-mimetic resistance in DLBCL.

Cell death & disease·2025
Same author

Computational modelling of aggressive B-cell lymphoma.

Biochemical Society transactions·2025
Same author

Design, synthesis and evaluation of pyrrolobenzodiazepine (PBD)-based PROTAC conjugates for the selective degradation of the NF-κB RelA/p65 subunit.

RSC medicinal chemistry·2025
Same author

Systems biology-enabled targeting of NF-κΒ and BCL2 overcomes microenvironment-mediated BH3-mimetic resistance in DLBCL.

bioRxiv : the preprint server for biology·2024

Related Experiment Video

Updated: Jun 11, 2026

Holistic Facial Composite Creation and Subsequent Video Line-up Eyewitness Identification Paradigm
09:49

Holistic Facial Composite Creation and Subsequent Video Line-up Eyewitness Identification Paradigm

Published on: December 24, 2015

Targeting the "partners in crime".

Chris Pepper1

  • 1Cardiff University.

Blood
|July 10, 2010
PubMed
Summary

The novel HSP90 inhibitor 17-DMAG effectively targets and eliminates chronic lymphocytic leukemia (CLL) cells by inhibiting NF-B. This research presents a promising new therapeutic strategy for treating CLL.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Chronic lymphocytic leukemia (CLL) is a heterogeneous hematologic malignancy.
  • Current therapies for CLL have limitations and resistance can develop.
  • Targeting key signaling pathways in cancer cells is a crucial therapeutic strategy.

Discussion:

  • HSP90 inhibition disrupts multiple oncogenic pathways crucial for CLL cell survival.
  • 17-DMAG demonstrates potent and selective cytotoxicity against CLL cells in preclinical models.
  • The mechanism involves the targeted inhibition of the NF-B signaling pathway.

Key Insights:

  • 17-DMAG exhibits significant anti-leukemic activity in both in vitro and in vivo CLL models.
  • Selective targeting of HSP90 by 17-DMAG leads to degradation of client proteins essential for CLL.

More Related Videos

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

Related Experiment Videos

Last Updated: Jun 11, 2026

Holistic Facial Composite Creation and Subsequent Video Line-up Eyewitness Identification Paradigm
09:49

Holistic Facial Composite Creation and Subsequent Video Line-up Eyewitness Identification Paradigm

Published on: December 24, 2015

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

  • Inhibition of NF-B is a critical mediator of 17-DMAG's therapeutic effect.

    • Outlook:

    • 17-DMAG represents a promising novel therapeutic agent for CLL treatment.
    • Further clinical investigation of 17-DMAG in CLL patients is warranted.
    • Targeted HSP90 inhibition offers a potential new avenue for overcoming treatment resistance in CLL.